Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | -7.18%63.07M | -20.92%277.62M | -4.13%222.09M | 16.21%145.4M | 21.90%67.95M | 2.63%351.08M | 0.75%231.67M | -16.87%125.12M | -2.39%55.75M | -10.45%342.08M |
Operating revenue | -7.18%63.07M | -20.92%277.62M | -4.13%222.09M | 16.21%145.4M | 21.90%67.95M | 2.63%351.08M | 0.75%231.67M | -16.87%125.12M | -2.39%55.75M | -10.45%342.08M |
Total operating cost | 16.57%79.04M | 9.74%325.37M | 11.97%225.75M | 25.16%140.9M | 35.43%67.8M | 5.18%296.49M | 5.82%201.61M | -11.02%112.58M | -8.20%50.06M | -4.84%281.88M |
Operating cost | 11.37%52.39M | -3.17%216.74M | 2.02%154.53M | 17.91%96.01M | 32.18%47.04M | 0.93%223.82M | -0.03%151.48M | -19.01%81.43M | -12.09%35.59M | -7.22%221.77M |
Operating tax surcharges | 57.23%1.68M | 21.88%4.47M | 10.58%2.71M | 15.09%1.71M | 38.85%1.07M | 61.03%3.66M | 72.79%2.45M | 26.13%1.49M | -4.23%769.16K | 30.31%2.28M |
Operating expense | -8.13%3.12M | 108.96%20.03M | 233.49%15.84M | 142.14%8.32M | 114.98%3.4M | 89.27%9.59M | 26.87%4.75M | 35.85%3.44M | 27.94%1.58M | -12.04%5.06M |
Administration expense | 33.60%14.9M | 30.12%54.65M | 18.51%36.81M | 23.26%24.5M | 19.43%11.15M | 1.88%42M | 36.44%31.06M | 36.28%19.88M | 22.54%9.34M | 16.24%41.22M |
Financial expense | 155.46%4.74M | 158.47%9.73M | 162.21%5.87M | 283.39%3.71M | 116,797.44%1.86M | 292.15%3.76M | 255.17%2.24M | 175.09%967.57K | 99.63%-1.59K | -12.83%-1.96M |
-Interest expense (Financial expense) | 97.51%4.92M | 72.77%11.73M | 58.28%7.49M | 71.77%4.85M | 184.01%2.49M | 218.08%6.79M | 284.09%4.73M | 527.73%2.82M | 141.09%877.33K | 55.12%2.14M |
-Interest Income (Financial expense) | 58.45%-281.61K | 33.30%-2.19M | 30.68%-1.85M | 35.54%-1.24M | 26.35%-677.7K | 21.46%-3.28M | 2.18%-2.66M | -8.31%-1.92M | -13.09%-920.15K | -29.83%-4.17M |
Research and development | -32.85%2.21M | 44.70%19.76M | 3.65%9.99M | 23.54%6.64M | 17.85%3.29M | 1.10%13.65M | -22.99%9.64M | -40.02%5.38M | -42.20%2.79M | -15.31%13.51M |
Credit Impairment Loss | 306.27%9.11M | -33.85%-28.28M | -19,822.35%-6.65M | -840.07%-7.33M | 767.01%2.24M | -38.97%-21.13M | 101.07%33.7K | 1,359.52%989.85K | -115.63%-336.05K | -180.73%-15.2M |
Asset Impairment Loss | 91.80%2.42M | -36.83%-6.55M | -57.11%-2.58M | 118.80%157.69K | 1,721.68%1.26M | -119.94%-4.79M | -32.38%-1.64M | -10.61%-838.85K | -59.43%69.39K | -36.07%-2.18M |
Other net revenue | ||||||||||
Fair value change income | ---- | ---- | ---- | ---- | ---- | -88.08%25.32K | ---- | ---- | ---- | 102.81%212.33K |
Invest income | ---- | -70.11%657.27K | -57.98%562.92K | -58.83%401.27K | -88.24%48.33K | -56.69%2.2M | -55.09%1.34M | -59.12%974.68K | 46.41%410.96K | 2.07%5.08M |
Asset deal income | --35.43K | -10,182.26%-360.03K | -616.28%-825.98K | ---- | ---- | -100.40%-3.5K | -75.08%159.99K | ---- | ---- | -20.75%873.23K |
Other revenue | 5.20%841.82K | -13.72%3.04M | -9.93%2.69M | -41.59%1.21M | -8.98%800.23K | 88.54%3.52M | 128.94%2.98M | 108.11%2.07M | 269.29%879.14K | 57.62%1.87M |
Operating profit | -178.96%-3.56M | -330.31%-79.25M | -131.78%-10.47M | -106.74%-1.06M | -32.80%4.51M | -32.33%34.41M | -17.63%32.93M | -40.53%15.73M | 24.47%6.71M | -40.96%50.85M |
Add:Non operating Income | 122.95%39.35K | 3,346.76%738.7K | 702.09%110.93K | 344.96%96.85K | 63.04%17.65K | 273.95%21.43K | -6.19%13.83K | -78.99%21.77K | -75.40%10.83K | -99.86%5.73K |
Less:Non operating expense | 71.52%137.57K | -49.96%288.97K | -51.29%206.69K | 103.86%109.77K | 71.93%80.2K | -41.08%577.48K | 95.83%424.35K | 70.79%53.85K | 194.36%46.65K | 76.72%980.03K |
Total profit | -182.28%-3.66M | -332.76%-78.8M | -132.48%-10.56M | -106.83%-1.07M | -33.38%4.44M | -32.12%33.85M | -18.25%32.52M | -40.81%15.7M | 23.16%6.67M | -44.38%49.88M |
Less:Income tax cost | -1,141.78%-3.87M | -379.21%-11.8M | -168.40%-2.61M | -113.29%-207.35K | -72.55%371.45K | -60.38%4.23M | -53.63%3.81M | -68.86%1.56M | 12.39%1.35M | 3.15%10.67M |
Net profit | -94.76%213.48K | -326.14%-67M | -127.71%-7.95M | -106.12%-865.86K | -23.40%4.07M | -24.43%29.63M | -9.03%28.71M | -34.28%14.14M | 26.25%5.32M | -50.57%39.21M |
Net profit from continuing operation | -94.76%213.48K | -326.14%-67M | ---- | -106.12%-865.86K | -23.40%4.07M | -24.43%29.63M | ---- | -34.28%14.14M | 26.25%5.32M | -50.57%39.21M |
Less:Minority Profit | 35.01%-1.04M | -493.06%-10.45M | -292.00%-4.51M | -194.37%-2.37M | -197.92%-1.6M | -79.99%2.66M | -71.65%2.35M | -19.91%2.51M | 343.43%1.64M | 250.72%13.28M |
Net profit of parent company owners | -77.89%1.25M | -309.69%-56.55M | -113.07%-3.44M | -87.07%1.5M | 54.15%5.67M | 4.02%26.97M | 13.26%26.36M | -36.73%11.63M | -4.21%3.68M | -65.68%25.93M |
Earning per share | ||||||||||
Basic earning per share | -83.33%0.01 | -300.00%-0.56 | -111.11%-0.03 | -91.67%0.01 | 50.00%0.06 | 0.00%0.28 | 8.00%0.27 | -40.00%0.12 | 0.00%0.04 | -65.85%0.28 |
Diluted earning per share | -83.33%0.01 | -300.00%-0.56 | -111.11%-0.03 | -91.67%0.01 | 50.00%0.06 | 0.00%0.28 | 8.00%0.27 | -40.00%0.12 | 0.00%0.04 | -65.85%0.28 |
Other composite income | ||||||||||
Total composite income | -94.76%213.48K | -326.14%-67M | -127.71%-7.95M | -106.12%-865.86K | -23.40%4.07M | -24.43%29.63M | -9.03%28.71M | -34.28%14.14M | 26.25%5.32M | -50.57%39.21M |
Total composite income of parent company owners | -77.89%1.25M | -309.69%-56.55M | -113.07%-3.44M | -87.07%1.5M | 54.15%5.67M | 4.02%26.97M | 13.26%26.36M | -36.73%11.63M | -4.21%3.68M | -65.68%25.93M |
Total composite income of minority owners | 35.01%-1.04M | -493.06%-10.45M | -292.00%-4.51M | -194.37%-2.37M | -197.92%-1.6M | -79.99%2.66M | -71.65%2.35M | -19.91%2.51M | 343.43%1.64M | 250.72%13.28M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | -- | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.